Vertex reported third-quarter product revenue of $3.44 billion, up 12 percent from a year earlier, and GAAP net income of $654 million, or $2.56 a share. It raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion. Casgevy revenue was $99.2 million and Journavx revenue was $58.3 million.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- Vertex withdraws EU filings for toddler CF drugsSunday, September 20, 2026
- Court says Vertex Casgevy fertility perk is a kickbackSaturday, September 5, 2026
- Vertex closes $10 billion Crinetics acquisitionWednesday, September 2, 2026
- Crinetics shareholders approve Vertex's $10 billion buyoutTuesday, September 1, 2026